Food and Drug Administration announced on April 30, 2026, that it is considering removing several popular GLP-1 medications from the agencys 503B bulks list a decision that could significantly reduce the supply of compounded versions of these drugs in the United States
These results are significantly higher than diet and exercise alone, though individual results vary based on genetics, lifestyle adherence, and metabolic factors that PlexusDx genetic testing can help clarify
Watkins PB, Kaplowitz N, Slattery JT, et al
Pharmacy Profile Name: Strive Pharmacy (strivepharmacy.com) HQ: Gilbert, AZ Pharmacy Type: 503A compounding pharmacy Accreditations: NABP + PCAB + LegitScript (triple-accredited) GLP-1 Products: Semaglutide, Tirzepatide (injectable
Suggestion: Try different amounts (max 5g / day!) At different times of the day and check what is helping you